Account

Sign in to access your account and subscription

Fosamax and the Public Hazards Discovery Doctrine

An observation can be made about the typical method through which mass pharmaceutical litigation begins. Initially, the plaintiff files a lawsuit and serves the manufacturer with written discovery requests, seeking information pertaining to adverse events, clinical trials, direct-to-consumer marketing, and the like. The manufacturer objects to each and every request and does not provide one document. The manufacturer then delays, and the plaintiff frets and finally a compromise is worked out whereby limited production will be obtained; attached to that production will be a manufacturer-imposed presumption of confidentiality. At the same time, while the manufacturer strives to keep secret the internal documents showing what it knew and when it knew it, it will issue a press release talking about the wonderful medicine, claiming it is being wrongfully sued and saying that it has never had a reason to think the medicine was unsafe.

16 minute read June 28, 2006 at 04:01 PM
By
Timothy M. O'Brien
Fosamax and the Public Hazards Discovery Doctrine

Part One of a Two-Part Series

This premium content is locked for LawJournalNewsletters subscribers only

ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN LawJournalNewsletters

  • Stay current on the latest information, rulings, regulations, and trends
  • Includes practical, must-have information on copyrights, royalties, AI, and more
  • Tap into expert guidance from top entertainment lawyers and experts

Already have an account? Sign In Now

For enterprise-wide or corporate access, please contact Customer Service at [email protected] or call 1-877-256-2473.

NOT FOR REPRINT

© 2026 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Continue Reading

The combination of increasing operating costs and uncertain government reimbursement funding continues to place health care providers under financial pressure, and in many cases, financial distress. Given the importance of Medicare/Medicaid funding of claims under provider agreements with the federal government, how courts interpret and apply the interplay between the Bankruptcy Code and Medicare Program Act determines the disposition of hundreds of millions of dollars of claims for reimbursement that support the health care system.

April 30, 2026

As AI becomes embedded in everyday business and legal operations, organizations are confronting a new expectation: simply disclosing AI use is no longer enough. A critical shift is taking place in the legal industry: transparency is no longer just about disclosure; it’s about comprehension.

April 30, 2026